SCHEMBL16433477

SCHEMBL16433477

CNC1CCCc2c1[nH]c1ccc(Cl)cc21

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
MAPT P10636 3/20 0.71
MEN1 O00255 3/20 0.71
KMT2A Q03164 3/20 0.71
GLA P06280 1/20 0.71
MAPK1 P28482 1/20 0.68
SIRT1 Q96EB6 9/20 0.59
SIRT2 Q8IXJ6 3/20 0.58
SIRT3 Q9NTG7 2/20 0.58
DHODH Q02127 1/20 0.58
LMNA P02545 2/20 0.56
TP53 P04637 1/20 0.56
TSHR P16473 1/20 0.53
HTR2A P28223 2/20 0.52
HTR2C P28335 2/20 0.52
BRD3 Q15059 1/20 0.52
GAA P10253 1/20 0.52
CASP6 P55212 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148681 0.84 ALOX15 (0.68) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4163867 0.84 CYP2D6 (0.70) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5456549 0.83 ALOX15 (0.70) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4148059 0.83 MAPT (0.63) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4147497 0.82 CYP2D6 (0.74) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL16433472 0.82 SIRT1 (0.63) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5456610 0.81 ALOX15 (1.00) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4150562 0.81 ALOX15 (0.60) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4143028 0.80 MAPT (0.63) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4134717 0.80 DHODH (0.66) ALOX15SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR ALOX15 1442/4885SMN1; SMN2 4619/4885MAPT 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.